UBS Group
LVAC

UBS Group’s LAVA Medtech Acquisition Corp. Class A Common Stock LVAC Stock Holding History

UBS Group’s Portfolio LVAC Stock Details LVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5
Closed – – 11507
2022
Q3 		$0 Hold
5
– – ﹤0.01% 11415
2022
Q2 		$0 Buy
+5
New +$50 ﹤0.01% 11399

Other funds holding LVAC

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
GL
Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

UBS Group's LVAC Position: Q4 2022 in Review

UBS Group sold out of LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) in Q4 2022, closing a stake of 5 shares.

UBS Group first reported a position in LVAC in Q2 2022 and held it in 2 quarters. The position peaked at $0 in Q3 2022. 53 funds tracked by Wall St. Rank hold LVAC as of Q4 2022.

  • UBS Group reported no remaining LAVA Medtech Acquisition Corp. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
  • UBS Group sold 5 LAVA Medtech Acquisition Corp. Class A Common Stock shares in Q4 2022.
  • UBS Group first reported a position in LAVA Medtech Acquisition Corp. Class A Common Stock in Q2 2022 and held it in 2 quarters.
  • UBS Group's LAVA Medtech Acquisition Corp. Class A Common Stock position peaked at $0 in Q3 2022.
  • 53 funds tracked by Wall St. Rank held LAVA Medtech Acquisition Corp. Class A Common Stock as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.